The global migraine drugs market reached a value of US$2.92 bn in 2017 and is expected to reach a value of US$3.82 bn by 2026. The global migraine drugs market is expected to register a steady CAGR 3.70% between 2019 and 2026. The market is mainly segmented into three segments namely Treatment, Route of Administration, and Distribution Channel.
The report analyzes and forecasts the migraine drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of migraine drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major migraine drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of migraine drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of migraine drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global migraine drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the migraine drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of migraine drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Migraine Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. High prevalence of migraine and increasing transition from episodic to chronic migraine
4.3.1.2. Increasing investment in R&D and promising pipeline of novel drugs
4.3.1.3. Aging population and increasing proportion of female population
4.3.1.4. Increasing awareness among patients and high promotional investment by key players
4.3.2. Restraints
4.3.2.1. Fragmented Market with vast availability of generic drugs
4.3.2.2. Ongoing investment in alternative therapies
4.3.3. Opportunities
4.3.4. Trends
4.4. Migraine Drugs Market Analysis and Forecast, 2017 – 2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s five forces analysis
4.6. Value Chain Analysis
4.7. Global Prevalence of Migraine
4.8. Pipeline Analysis
4.8.1. Pipeline Analysis: Migraine Treatment Drugs
4.8.2. Pipeline Analysis: Migraine Treatment Devices
4.9. Market Outlook
5. Global Migraine Drugs Market Analysis and Forecasts, By Treatment
5.1. Introduction & Definition
5.2. Key Findings
5.3. Market Size (US$ Mn) Forecast, By Treatment
5.3.1. Abortive
5.3.1.1. Triptans
5.3.1.2. Ergot Alkaloids
5.3.1.3. Others
5.3.2. Prophylactic
5.3.2.1. Botulinum Toxin
5.3.2.2. Topiramate
5.3.2.3. Others
5.4. New (Pipeline) Migraine Drugs Market Revenue (US$) Forecast, 2017-2025
5.5. Market Attractiveness, By Treatment
5.6. Key Trends
6. Global Migraine Drugs Market Analysis and Forecasts, By Route of Administration
6.1. Introduction & Definition
6.2. Key Findings
6.3. Market Size (US$ Mn) Forecast, By Route of Administration
6.3.1. Oral
6.3.2. Injectable
6.3.3. Other
6.4. Market Attractiveness, By Route of Administration
6.5. Key Trends
7. Global Migraine Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.3. Market Size (US$ Mn) Forecast, By Distribution Chanel
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, By Distribution Channel
7.5. Key Trends
8. Global Migraine Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Global Market Scenario
8.3. Market Size (US$ Mn) Forecast, By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Attractiveness, By Region
8.5. Key Trends, By Region
9. North America Migraine Drugs Market Analysis and Forecast
9.1. Key Findings
9.2. Market Size (US$ Mn) Forecast, By Treatment
9.2.1. Abortive
9.2.1.1. Triptans
9.2.1.2. Ergot Alkaloids
9.2.1.3. Others
9.2.2. Prophylactic
9.2.2.1. Botulinum Toxin
9.2.2.2. Topiramate
9.2.2.3. Others
9.3. Market Size (US$ Mn) Forecast, By Route of Administration
9.3.1. Oral
9.3.2. Injectable
9.3.3. Others
9.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacies
9.4.3. Others
9.5. Market Size by Value (US$ Mn) Forecast, By Country
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By Route of Administration
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe Migraine Drugs Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, By Treatment
10.2.1. Abortive
10.2.1.1. Triptans
10.2.1.2. Ergot Alkaloids
10.2.1.3. Others
10.2.2. Prophylactic
10.2.2.1. Botulinum Toxin
10.2.2.2. Topiramate
10.2.2.3. Others
10.3. Market Size (US$ Mn) Forecast, By Route of Administration
10.3.1. Oral
10.3.2. Injectable
10.3.3. Others
10.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Others
10.5. Market Size by Value (US$ Mn) Forecast, By Country
10.5.1. Germany
10.5.2. France
10.5.3. U.K.
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Asia Pacific Anti-migraine Drugs Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, By Treatment
11.2.1. Abortive
11.2.1.1. Triptans
11.2.1.2. Ergot Alkaloids
11.2.1.3. Others
11.2.2. Prophylactic
11.2.2.1. Botulinum Toxin
11.2.2.2. Topiramate
11.2.2.3. Others
11.3. Market Size (US$ Mn) Forecast, By Route of Administration
11.3.1. Oral
11.3.2. Injectable
11.3.3. Others
11.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Others
11.5. Market Size by Value (US$ Mn) Forecast, By Country
11.5.1. India
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country
12. Latin America Anti-migraine Drugs Market Analysis and Forecast
12.1. Key Findings
12.2. Market Size (US$ Mn) Forecast, By Treatment
12.2.1. Abortive
12.2.1.1. Triptans
12.2.1.2. Ergot Alkaloids
12.2.1.3. Others
12.2.2. Prophylactic
12.2.2.1. Botulinum Toxin
12.2.2.2. Topiramate
12.2.2.3. Others
12.3. Market Size (US$ Mn) Forecast, By Route of Administration
12.3.1. Oral
12.3.2. Injectable
12.3.3. Others
12.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Others
12.5. Market Size by Value (US$ Mn) Forecast, By Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country
13. Middle East and Africa Anti-migraine Drugs Market Analysis and Forecast
13.1. Key Findings
13.2. Market Size (US$ Mn) Forecast, By Treatment
13.2.1. Abortive
13.2.1.1. Triptans
13.2.1.2. Ergot Alkaloids
13.2.1.3. Others
13.2.2. Prophylactic
13.2.2.1. Botulinum Toxin
13.2.2.2. Topiramate
13.2.2.3. Others
13.3. Market Size (US$ Mn) Forecast, By Route of Administration
13.3.1. Oral
13.3.2. Injectable
13.3.3. Others
13.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Others
13.5. Market Size by Value (US$ Mn) Forecast, By Country
13.5.1. Saudi Arabia
13.5.2. South Africa
13.5.3. Israel
13.5.4. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. AstraZeneca Plc.
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Product Portfolio
14.2.1.3. SWOT Analysis
14.2.1.4. Financial Overview
14.2.1.5. Strategic Overview
14.2.2. Allergan Plc.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Product Portfolio
14.2.2.3. SWOT Analysis
14.2.2.4. Financial Overview
14.2.2.5. Strategic Overview
14.2.3. GlaxoSmithKline Plc.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Product Portfolio
14.2.3.3. SWOT Analysis
14.2.3.4. Financial Overview
14.2.3.5. Strategic Overview
14.2.4. Novartis AG
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Product Portfolio
14.2.4.3. SWOT Analysis
14.2.4.4. Financial Overview
14.2.4.5. Strategic Overview
14.2.5. Pfizer, Inc.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Product Portfolio
14.2.5.3. SWOT Analysis
14.2.5.4. Financial Overview
14.2.5.5. Strategic Overview
14.2.6. Valeant Pharmaceuticals International, Inc.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Product Portfolio
14.2.6.3. SWOT Analysis
14.2.6.4. Financial Overview
14.2.6.5. Strategic Overview
14.2.7. Teva Pharmaceutical Industries, Ltd.
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Product Portfolio
14.2.7.3. SWOT Analysis
14.2.7.4. Financial Overview
14.2.7.5. Strategic Overview
14.2.8. Eli Lilly & Company
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Product Portfolio
14.2.8.3. SWOT Analysis
14.2.8.4. Financial Overview
14.2.8.5. Strategic Overview
14.2.9. Merck & Co., Inc.
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Product Portfolio
14.2.9.3. SWOT Analysis
14.2.9.4. Financial Overview
14.2.9.5. Strategic Overview
14.2.10. Janssen Pharmaceutical Company (Johnson & Johnson)
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Product Portfolio
14.2.10.3. SWOT Analysis
14.2.10.4. Financial Overview
14.2.10.5. Strategic Overview
14.2.11. Endo Pharmaceutical Inc.
14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.11.2. Product Portfolio
14.2.11.3. SWOT Analysis
14.2.11.4. Financial Overview
14.2.11.5. Strategic Overview
14.2.12. Zosano Pharma Corporation
14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.12.2. Product Portfolio
14.2.12.3. SWOT Analysis
14.2.12.4. Financial Overview
14.2.12.5. Strategic Overview
14.2.13. Alder BioPharmaceutical, Inc.
14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.13.2. Product Portfolio
14.2.13.3. SWOT Analysis
14.2.13.4. Financial Overview
14.2.13.5. Strategic Overview
14.2.14. Avanir Pharmaceuticals, Inc.
14.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.14.2. Product Portfolio
14.2.14.3. SWOT Analysis
14.2.14.4. Financial Overview
14.2.14.5. Strategic Overview
14.2.15. Eisai Co., Ltd.
14.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.15.2. Product Portfolio
14.2.15.3. SWOT Analysis
14.2.15.4. Financial Overview
14.2.15.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers